Companies › Chipscreen Biosciences
7 active drug programs in 8 registered trials: 4 Phase 1, 3 Phase 3, 1 Phase 2; Oncology, Immunology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sintilimab Programmed cell death protein 1 antagonist | PDCD1 | Phase 3 | Colorectal Cancer | May 2028 |
| Tucidinostat HDAC inhibitor | HDAC (class I/II) | Phase 3 | Colorectal Cancer; Lymphoma, T-Cell, Peripheral | May 2028 |
| Ibcasertib Serine/threonine-protein kinase Aurora-B inhibitor; Vascular endothelial growth factor receptor inhibitor | AURKB, FLT1, FLT4, KDR | Phase 2 | Pancreatic Ductal Adenocarcinoma | Feb 2027 |
| CS23546 | – | Phase 1 | Advanced Tumors | Feb 2027 |
| CS32582 | – | Phase 1 | Plaque Psoriasis | Sep 2027 |
| NWY001 | – | Phase 1 | Advanced Solid Tumor | May 2028 |
| CS231295 | – | Phase 1 | Neoplasms | Apr 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06492915 | Ibcasertib | Phase 2 | Pancreatic Ductal Adenocarcinoma | Oncology | Feb 2027 |
| NCT06245122 | CS23546 | Phase 1 | Advanced Tumors | Oncology | Feb 2027 |
| NCT07129382 | CS32582 | Phase 1 | Plaque Psoriasis | Immunology | Sep 2027 |
| NCT05979155 | NWY001 | Phase 1 | Advanced Solid Tumor | Oncology | May 2028 |
| NCT06497985 | Tucidinostat | Phase 3 | Colorectal Cancer | Oncology | May 2028 |
| NCT06497985 | Sintilimab | Phase 3 | Colorectal Cancer | Oncology | May 2028 |
| NCT06902350 | CS231295 | Phase 1 | Neoplasms | Oncology | Apr 2029 |
| NCT06947967 | Tucidinostat | Phase 3 | Lymphoma, T-Cell, Peripheral | Oncology | Dec 2032 |
Hutchmed AstraZeneca Akeso Merck & Co. (MSD) Chia Tai Tianqing Pharmaceutical Group Takeda AO GENERIUM Avalyn Pharma Mannkind Ocular Therapeutix
Hutchmed MediLink Therapeutics (Suzhou) LaNova Medicines Arcus Biosciences Criterium
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.